title: Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation.
abstract: Ninety-six AML patients in 1st CR were evaluated for peak CD34+ cell levels in peripheral blood (PB) during PBSC mobilization and harvest. Distribution of CD34+ cell peaks was determined and cases were grouped on the basis of 50th and 75th percentile: group A, those having a CD34+ cell peak ≤70 × 10(9)/L (n=48); group B, those having a CD34+ cell peak between 70 and 183 × 10(9)/L (n=24); group C, those having a CD34+ cell peak >183 × 10(9)/L (n=24). Irrespective of post-remission treatment received, group A had a disease free survival (DFS) of 73%, group B a DFS of 51% and group C of 30% (P=0.0003). In intermediate cytogenetic risk patients, those treated by autologous transplantation had a DFS of 68, 33 and 14% in the groups A, B and C, respectively, (P=0.01) whereas after allogeneic transplantation DFS was 87% in group A+B vs 50% in group C (P=0.009). The peak of CD34+ cells in PB, was an independent predictor for DFS in multivariate analysis.
authors.affiliation: Bone Marrow Transplantation Unit, Azienda Ospedaliera Policlinico Vittorio Emanuele, Catania, Italy. giuseppe.milone@gmail.com
authors.forename: G
authors.initials: G
authors.lastname: Milone
authors.forename: M
authors.initials: M
authors.lastname: Poidomani
authors.forename: S
authors.initials: S
authors.lastname: Leotta
authors.forename: G
authors.initials: G
authors.lastname: Avola
authors.forename: M G
authors.initials: MG
authors.lastname: Camuglia
authors.forename: A
authors.initials: A
authors.lastname: Privitera
authors.forename: C
authors.initials: C
authors.lastname: Consoli
authors.forename: S
authors.initials: S
authors.lastname: Mercurio
authors.forename: M A
authors.initials: MA
authors.lastname: Romeo
authors.forename: A
authors.initials: A
authors.lastname: Di Marco
authors.forename: S
authors.initials: S
authors.lastname: Di Mercurio
authors.forename: A
authors.initials: A
authors.lastname: Spadaro
authors.forename: G A
authors.initials: GA
authors.lastname: Palumbo
authors.forename: P
authors.initials: P
authors.lastname: Tedeschi
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000097:blood; D018572:Disease-Free Survival; D005260:Female; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D012307:Risk Factors; D015996:Survival Rate; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous
chemical_list: D018952:Antigens, CD34